MRK Merck & Co Inc

Price (delayed)

$124.38

Market cap

$315.03B

P/E Ratio

136.68

Dividend/share

$3.04

EPS

$0.91

Enterprise value

$343.67B

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the ...

Highlights
The gross profit has grown by 9% year-on-year and by 3.8% since the previous quarter
The revenue has grown by 6% YoY and by 2.1% from the previous quarter
The P/E is 86% higher than the 5-year quarterly average of 73.4 but 49% lower than the last 4 quarters average of 268.8
Merck's equity has decreased by 14% YoY but it has increased by 7% from the previous quarter
The EPS has plunged by 82% YoY
The net income has dropped by 82% year-on-year

Key stats

What are the main financial stats of MRK
Market
Shares outstanding
2.53B
Market cap
$315.03B
Enterprise value
$343.67B
Valuations
Price to book (P/B)
7.8
Price to sales (P/S)
5.13
EV/EBIT
67.35
EV/EBITDA
38.32
EV/Sales
5.6
Earnings
Revenue
$61.4B
EBIT
$5.1B
EBITDA
$8.97B
Free cash flow
$11.04B
Per share
EPS
$0.91
Free cash flow per share
$4.36
Book value per share
$15.94
Revenue per share
$24.24
TBVPS
$26.49
Balance sheet
Total assets
$105.85B
Total liabilities
$65.43B
Debt
$34.22B
Equity
$40.36B
Working capital
$6.35B
Liquidity
Debt to equity
0.85
Current ratio
1.25
Quick ratio
0.68
Net debt/EBITDA
3.19
Margins
EBITDA margin
14.6%
Gross margin
74.4%
Net margin
3.8%
Operating margin
6.9%
Efficiency
Return on assets
2.2%
Return on equity
5.8%
Return on invested capital
7.2%
Return on capital employed
6.3%
Return on sales
8.3%
Dividend
Dividend yield
2.44%
DPS
$3.04
Payout ratio
334.1%

MRK stock price

How has the Merck stock price performed over time
Intraday
-1.04%
1 week
-0.85%
1 month
-4.85%
1 year
12.67%
YTD
14.09%
QTD
0.47%

Financial performance

How have Merck's revenue and profit performed over time
Revenue
$61.4B
Gross profit
$45.66B
Operating income
$4.25B
Net income
$2.31B
Gross margin
74.4%
Net margin
3.8%
MRK's net margin has dropped by 83% year-on-year
The net income has dropped by 82% year-on-year
Merck's operating income has soared by 81% from the previous quarter but it has plunged by 74% YoY
Merck's operating margin has surged by 77% QoQ but it has shrunk by 75% YoY

Growth

What is Merck's growth rate over time

Valuation

What is Merck stock price valuation
P/E
136.68
P/B
7.8
P/S
5.13
EV/EBIT
67.35
EV/EBITDA
38.32
EV/Sales
5.6
The P/E is 86% higher than the 5-year quarterly average of 73.4 but 49% lower than the last 4 quarters average of 268.8
The EPS has plunged by 82% YoY
The price to book (P/B) is 16% higher than the 5-year quarterly average of 6.7 and 5% higher than the last 4 quarters average of 7.4
Merck's equity has decreased by 14% YoY but it has increased by 7% from the previous quarter
MRK's P/S is 9% above its 5-year quarterly average of 4.7 and 4.7% above its last 4 quarters average of 4.9
The revenue has grown by 6% YoY and by 2.1% from the previous quarter

Efficiency

How efficient is Merck business performance
The company's return on assets has shrunk by 82% YoY
Merck's ROE has plunged by 80% YoY
The ROIC has shrunk by 72% YoY but it has soared by 64% QoQ
The ROS has plunged by 70% YoY but it has soared by 66% from the previous quarter

Dividends

What is MRK's dividend history
DPS
$3.04
Dividend yield
2.44%
Payout ratio
334.1%
Recent dividends

Financial health

How did Merck financials performed over time
The total assets is 62% more than the total liabilities
MRK's quick ratio is down by 24% year-on-year
The current ratio has contracted by 13% YoY
MRK's debt is 15% smaller than its equity
The debt to equity has grown by 29% YoY but it has contracted by 9% from the previous quarter
Merck's equity has decreased by 14% YoY but it has increased by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.